NextCell Pharma AB (NXTCL) - Net Assets

Latest as of August 2025: Skr66.39 Million SEK ≈ $7.14 Million USD

Based on the latest financial reports, NextCell Pharma AB (NXTCL) has net assets worth Skr66.39 Million SEK (≈ $7.14 Million USD) as of August 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr76.73 Million ≈ $8.26 Million USD) and total liabilities (Skr10.34 Million ≈ $1.11 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NextCell Pharma AB (NXTCL) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Skr66.39 Million
% of Total Assets	86.52%
Annual Growth Rate	21.12%
5-Year Change	-55.77%
10-Year Change	881.39%
Growth Volatility	178.57

NextCell Pharma AB - Net Assets Trend (2015–2025)

This chart illustrates how NextCell Pharma AB's net assets have evolved over time, based on quarterly financial data. Also explore NXTCL total asset value for the complete picture of this company's asset base.

Annual Net Assets for NextCell Pharma AB (2015–2025)

The table below shows the annual net assets of NextCell Pharma AB from 2015 to 2025. For live valuation and market cap data, see NextCell Pharma AB market capitalisation.

Year	Net Assets	Change
2025-08-31	Skr66.39 Million ≈ $7.14 Million	-1.79%
2024-08-31	Skr67.60 Million ≈ $7.27 Million	-10.73%
2023-08-31	Skr75.73 Million ≈ $8.15 Million	-34.46%
2022-08-31	Skr115.54 Million ≈ $12.43 Million	-23.02%
2021-08-31	Skr150.09 Million ≈ $16.15 Million	+472.47%
2020-08-31	Skr26.22 Million ≈ $2.82 Million	+14.19%
2019-08-31	Skr22.96 Million ≈ $2.47 Million	+355.44%
2018-08-31	Skr5.04 Million ≈ $542.53K	-73.57%
2017-08-31	Skr19.07 Million ≈ $2.05 Million	+181.96%
2016-08-31	Skr6.76 Million ≈ $728.00K	-30.77%
2015-08-31	Skr9.77 Million ≈ $1.05 Million	--

Equity Component Analysis

This analysis shows how different components contribute to NextCell Pharma AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 5687.8% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (August 2025)

Component	Amount	Percentage
Common Stock	Skr22.84 Million	34.40%
Other Components	Skr248.41 Million	374.17%
Total Equity	Skr66.39 Million	100.00%

NextCell Pharma AB Competitors by Market Cap

The table below lists competitors of NextCell Pharma AB ranked by their market capitalization.

Company	Market Cap
Ornapaper Bhd KLSE:5065	$13.22 Million
Indiana Resources Ltd AU:IDA	$13.22 Million
Origin Agritech Ltd NASDAQ:SEED	$13.22 Million
INVO Fertility, Inc. NASDAQ:IVF	$13.23 Million
Mg Internation PA:ALMGI	$13.21 Million
Nixxy, Inc. NASDAQ:NIXX	$13.21 Million
Volex Plc LSE:VLX	$13.21 Million
Putprop Ltd JSE:PPR	$13.21 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in NextCell Pharma AB's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 67,598,961 to 66,389,086, a change of -1,209,875 (-1.8%).
Net loss of 35,143,091 reduced equity.
Other factors increased equity by 33,933,216.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Skr-35.14 Million	-52.94%
Other Changes	Skr33.93 Million	+51.11%
Total Change	Skr-	-1.79%

Book Value vs Market Value Analysis

This analysis compares NextCell Pharma AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 1.27x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has increased from 1.13x to 1.27x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2015-08-31	Skr0.98	Skr1.10	x
2016-08-31	Skr1.29	Skr1.10	x
2017-08-31	Skr2.40	Skr1.10	x
2018-08-31	Skr0.30	Skr1.10	x
2019-08-31	Skr1.47	Skr1.10	x
2020-08-31	Skr1.18	Skr1.10	x
2021-08-31	Skr4.94	Skr1.10	x
2022-08-31	Skr1.68	Skr1.10	x
2023-08-31	Skr1.10	Skr1.10	x
2024-08-31	Skr0.92	Skr1.10	x
2025-08-31	Skr0.87	Skr1.10	x

Capital Efficiency Dashboard

This dashboard shows how efficiently NextCell Pharma AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -52.94%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -321.31%
• Asset Turnover: 0.14x
• Equity Multiplier: 1.16x
Recent ROE (-52.94%) is above the historical average (-90.56%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2015	-105.30%	-147840.73%	0.00x	1.26x	Skr-11.27 Million
2016	-168.72%	-1410.79%	0.09x	1.40x	Skr-12.09 Million
2017	-69.44%	-2560.93%	0.02x	1.13x	Skr-15.15 Million
2018	-278.34%	-2140.98%	0.08x	1.69x	Skr-14.54 Million
2019	-93.46%	-1184.14%	0.07x	1.16x	Skr-23.75 Million
2020	-67.47%	-496.24%	0.12x	1.14x	Skr-20.31 Million
2021	-16.37%	-627.92%	0.03x	1.04x	Skr-39.57 Million
2022	-29.50%	-609.88%	0.04x	1.08x	Skr-45.64 Million
2023	-52.57%	-393.65%	0.11x	1.17x	Skr-47.38 Million
2024	-62.07%	-393.45%	0.13x	1.20x	Skr-48.72 Million
2025	-52.94%	-321.31%	0.14x	1.16x	Skr-41.78 Million

Industry Comparison

This section compares NextCell Pharma AB's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $165,054,194
Average return on equity (ROE) among peers: -81.86%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
NextCell Pharma AB (NXTCL)	Skr66.39 Million	-105.30%	0.16x	$13.21 Million
2cureX AB (2CUREX)	$74.34 Million	-25.47%	0.06x	$4.90 Million
Ascelia Pharma AB (publ) (ACE)	$74.33 Million	-147.03%	0.17x	$40.96 Million
AcouSort AB (ACOU)	$15.58 Million	-57.51%	0.12x	$8.97 Million
Active Biotech AB (ACTI)	$188.64 Million	-118.73%	1.64x	$17.19 Million
Alzinova AB (ALZ)	$20.63 Million	-16.51%	0.08x	$4.97 Million
AlzeCure Pharma (ALZCUR)	$182.01 Million	-28.02%	0.03x	$18.18 Million
Annexin Pharmaceuticals AB (ANNX)	$18.81 Million	-234.16%	0.42x	$11.24 Million
Alligator Bioscience AB (ATORX)	$68.52 Million	-112.06%	0.43x	$14.33 Million
BioInvent International AB (BINV)	$219.00 Million	-63.86%	0.22x	$155.44 Million
BioArctic AB (publ) (BIOA-B)	$788.68 Million	-15.19%	0.14x	$2.59 Billion

About NextCell Pharma AB

ST:NXTCL Sweden Biotechnology

Market Cap

$13.21 Million

Skr122.76 Million SEK

Market Cap Rank

#26184 Global

#560 in Sweden

Share Price

Skr1.10

Change (1 day)

-4.01%

52-Week Range

Skr0.67 - Skr1.69

All Time High

Skr29.60